EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetics and Gut Microbiota in the Pathogenesis and Treatment of Bipolar Disorder (BD)

Shabnam Nohesara iD, Hamid Mostafavi Abdolmaleky iD, Ahmad Pirani, Sam Thiagalingam iD

Cells · 18.07.2025 · 14 (14) · 1104

DOI: 10.3390/cells14141104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 18.07.2025. Verfasst von Shabnam Nohesara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA. Hauptthemen laut MEDLINE: Bipolar Disorder, Gastrointestinal Microbiome, Epigenesis, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bipolar disorder (BD) is a multifactorial mental disease with a prevalence of 1–5% in adults, caused by complex interactions between genetic and environmental factors. Environmental factors contribute to gene expression alterations through epigenetic mechanisms without changing the underlying DNA sequences. Interactions between the gut microbiota (GM) and diverse external factors, such as nutritional composition, may induce epigenetic alterations and increase susceptibility to BD. While epigenetic mechanisms are involved in both the pathogenesis of BD and drug treatment responses, epigenetic marks could be employed as predictors and indicators of drug response. This review highlights recent studies on the potential role of epigenetic aberrations in the development and progression of BD. Next, we focus on drug response-related alterations in the epigenetic landscape, including DNA methylation, histone modifications, and non-coding RNAs. Afterward, we delve into the potential roles of GM-induced epigenetic changes in the pathogenesis of BD and GM-based therapeutic strategies aimed at improving BD outcomes through epigenetic modifications. We also discuss how BD drugs may exert beneficial effects through modulation of the GM and the epigenome. Finally, we consider future research strategies that could address existing challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderGastrointestinal MicrobiomeEpigenesis, GeneticHumansDNA MethylationAnimals

Stichwörter der Autor:innen

bipolar disorderdrug responseepigeneticmicrobiome

Autor:innen und Institutionen

  • Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
  • Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Mental Health Research Center, Psychosocial Health Research Institute, Iran University of Medical Sciences, Tehran 1449614535, Iran.
  • Department of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.

ORCID-Profile: Shabnam Nohesara, Hamid Mostafavi Abdolmaleky, Sam Thiagalingam

Zitieren

APA

Nohesara, S., Mostafavi Abdolmaleky, H., Pirani, A., & Thiagalingam, S. (2025). Epigenetics and Gut Microbiota in the Pathogenesis and Treatment of Bipolar Disorder (BD). Cells, 14(14), 1104. https://doi.org/10.3390/cells14141104

Vancouver

Nohesara S, Mostafavi Abdolmaleky H, Pirani A, Thiagalingam S. Epigenetics and Gut Microbiota in the Pathogenesis and Treatment of Bipolar Disorder (BD). Cells. 2025;14(14):1104. doi:10.3390/cells14141104

BibTeX
@article{Nohesara2025,
  author = {Nohesara, Shabnam and Mostafavi Abdolmaleky, Hamid and Pirani, Ahmad and Thiagalingam, Sam},
  title = {Epigenetics and Gut Microbiota in the Pathogenesis and Treatment of Bipolar Disorder (BD)},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {14},
  pages = {1104},
  doi = {10.3390/cells14141104}
}
Kostenlos starten →